Ianalumab is a fully human monoclonal antibody designed to deplete B cells via antibody-dependent cellular toxicity and inhibit BAFF-R-mediated signals of B cell function and survival.

The drug met its primary endpoints in a Chinese trial, while a Phase III trial in Sjögren's syndrome is currently underway in ...

Phase 3 results position telitacicept as potential best-in-disease profile in primary Sjögren's disease Telitacicept ...

"Novartis’ mAb could become first Sjögren’s disease drug after Phase III success" was originally created and published by ...

Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...

While Vor provided no details on the results, the company is now evaluating a global trial of the drug in the chronic immune ...

The China-based phase 3 trial of telitacicept in primary Sjögren's syndrome (pSS) met its primary endpoint, which focused on ...

Ocular and Systemic Morbidity in a Longitudinal Cohort of Sjögren's Syndrome Akpek EK, Mathews P, Hahn S, et al Ophthalmology. 2015;122:56-61 ...

Considering that IgG4-related syndrome also affects the parotid glands frequently, this overlap in symptoms further supports biopsy as a method to ensure the correct diagnosis of Sjögren's ...

Sjögren's syndrome is a chronic autoimmune disorder, characterized by lymphocytic infiltration and malfunction of the exocrine glands, resulting in dry mouth and eyes.

Patients with Sjögren syndrome have an increased risk for non-Hodgkin lymphoma. It is estimated that approximately 10% of patients with significant dry eye disease have Sjögren syndrome.